To our knowledge, we are the first to report the frequency and type of KRAS and BRAF mutations in Albanian patients with advanced CRC in order to introduce targeted therapy in the therapeutic modalities for management of this cancer in Albania. This evidence concerns the gene BRAF and cancer.